<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648150</url>
  </required_header>
  <id_info>
    <org_study_id>CHH_2020_32</org_study_id>
    <nct_id>NCT04648150</nct_id>
  </id_info>
  <brief_title>Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms</brief_title>
  <acronym>BOMP</acronym>
  <official_title>Evaluation of a Millimeter Wave Emission Bracelet -Type Medical Device for Improving Parkinson's Disease Symptoms: Multicenter, Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Remedee SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Parkinson's disease is a common neurodegenerative disease, with a prevalence of&#xD;
      around 2% in people over 65 years of age in France.&#xD;
&#xD;
      This pathology affects the dopaminergic pathway but also other systems: cholinergic,&#xD;
      noradrenergic and serotoninergic.&#xD;
&#xD;
      The symptoms of Parkinson's disease are motor but also non-motor with sleep, smell,&#xD;
      cognitive, psychiatric, digestive, urinary, dysautonomic, painful disorders. The discomfort&#xD;
      can be such that invasive and expensive solutions have been developed. Invasive or expensive&#xD;
      techniques (deep brain stimulation, lesional microsurgery by gamma knife or ultrasound,&#xD;
      duodopa or apokinon pumps) brought significant benefits to patients. Opportunities for&#xD;
      clinical improvement using less expensive and lighter devices should be sought.&#xD;
&#xD;
      The Remedee endorphin band device is a device that emits millimeter-band electromagnetic&#xD;
      waves on the wrist. The device stimulates subcutaneous nerve endings and activates a&#xD;
      physiological response leading to the release of endorphins in the brain. Endorphins are&#xD;
      involved in several physiological processes, including pain control.&#xD;
&#xD;
      Mu-opioid receptor (MOR) agonists do not only relieve pain, but have effects related to&#xD;
      mesolimbic dopaminergic pathways. Indeed, the opioid and dopaminergic systems are closely&#xD;
      linked at the cellular level. Endorphins, through inhibition of the release of the&#xD;
      neurotransmitter GABA upon binding to the μ receptor, are also linked to an increase in&#xD;
      dopamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention 1 Name : VERUM&#xD;
&#xD;
      Description :&#xD;
&#xD;
      Experimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then&#xD;
      delivery of a second active medical device for a period of 4 months.&#xD;
&#xD;
      Intervention 2 Name : SHAM&#xD;
&#xD;
      Description:&#xD;
&#xD;
      Control arm (SHAM): delivery of an inactive medical device for a period of 2 months of use&#xD;
      then delivery of an active medical device from M2 to M6 after inclusion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then delivery of a second active medical device for a period of 4 months.&#xD;
Control arm (SHAM): delivery of an inactive medical device for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>ratio 1 :1 in each centre on an online randomization module</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the effectiveness of two months of use of the Remedee Endorphin Band medical device in improving motor disorders in patients with Parkinson's disease</measure>
    <time_frame>two months after inclusion</time_frame>
    <description>The Movement Disorder Society Unified Parkinson Disease Rating Scale III (MDS-UPDRS III score evaluation see Appendix 1) will be performed under ON Dopa conditions and blinded from the randomization arm.&#xD;
The MDS-UPDRS III evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. Each parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total MDS-UPDRS III score is 199, indicating the worst possible disability from Parkinson disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>VERUM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms</intervention_name>
    <description>Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial</description>
    <arm_group_label>SHAM</arm_group_label>
    <arm_group_label>VERUM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Follow-up for Parkinson's disease for more than 5 years&#xD;
&#xD;
          -  Treatment stable for at least 3 months&#xD;
&#xD;
          -  Having retained sufficient autonomy to allow participation in the study&#xD;
&#xD;
          -  Hoehn and Yahr score in ON DOPA &lt;4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetic forms of the disease&#xD;
&#xD;
          -  EVA&gt; 7 over the previous week&#xD;
&#xD;
          -  Moderate to severe cognitive impairment&#xD;
&#xD;
          -  Pathology or condition (other than Parkinson's disease) that can generate motor&#xD;
             disorders&#xD;
&#xD;
          -  Allergy to metals and / or silicone&#xD;
&#xD;
          -  Dermatological pathology on the wrists&#xD;
&#xD;
          -  Metal object at one of the wrists (implanted metal material, piercing)&#xD;
&#xD;
          -  Presence of a tattoo on one of the wrists&#xD;
&#xD;
          -  Wrist circumference &lt;14.5 cm or&gt; 21 cm i.e. wrist incompatible with the MD template&#xD;
&#xD;
          -  Inability of the patient to put on and / or wear the template of the medical device&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amelie Yavchitz, PhD</last_name>
    <phone>01 48 03 64 54</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecile HUBSCH, PhD</last_name>
    <phone>01 48 03 68 90</phone>
    <email>chubsch@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Yavchitz</last_name>
      <phone>01 48 03 64 54</phone>
      <email>ayavchitz@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Cécile Hubsch</last_name>
      <phone>01 48 03 68 90</phone>
      <email>chubsch@for.paris</email>
    </contact_backup>
    <investigator>
      <last_name>Cécile Hubsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Voiron</name>
      <address>
        <city>Voiron</city>
        <zip>38506</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amélie YAVCHITZ</last_name>
      <phone>01 48 03 64 54</phone>
      <email>ayavchitz@for.paris</email>
    </contact>
    <investigator>
      <last_name>Gérard Mick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

